The Biosimilar Development Process

FDA’s abbreviated licensure pathway brings biosimilars into the market sooner, while still ensuring their safety and effectiveness. Learn more with Dr. Sue Lim, M.D., Director at FDA’s Center for Drug Evaluation and Research. For more information, visit www.FDA.gov/biosimilars